Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Irritation Potential of Products in Human Eyes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02714166
Recruitment Status : Completed
First Posted : March 21, 2016
Last Update Posted : March 30, 2017
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
To evaluate the human eye irritation potential of one test sunscreen formulation.

Condition or disease Intervention/treatment Phase
Sunscreening Agents Other: Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521) Other: Ophthalmic Ointment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Evaluation of the Irritation Potential of Products in Human Eyes
Actual Study Start Date : February 26, 2016
Actual Primary Completion Date : February 26, 2016
Actual Study Completion Date : February 26, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sun Exposure

Arm Intervention/treatment
Experimental: Sunscreen lotion Sun Protection Factor 50 (BAY987521)
Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Other: Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)
Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.

Ophthalmic Ointment
Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
Other: Ophthalmic Ointment
Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.




Primary Outcome Measures :
  1. Subjective assessment of discomfort in the eyes assessed by 5 point scale. [ Time Frame: Up to 1 day ]
  2. Intensity of Lacrimation assessed by 5 grading scale. [ Time Frame: Up to 1 day ]
  3. Intensity of Bulbar Conjunctiva Irritation assessed by 4 grading scale. [ Time Frame: Up to 1 day ]
  4. Intensity of Palpebral Conjunctiva Irritation assessed by 4 grading scale. [ Time Frame: Up to 1 day ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be healthy males or females between the ages of 18 to 60 years inclusive with no medical conditions of the eyes.
  • Do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the test period.
  • Willing to report any medications taken during the study.
  • Willing to have the test materials instilled into the eyes and follow all protocol requirements.
  • Have been informed and have given written consent to participate in the study.

Exclusion Criteria:

  • Has ocular disease or peri-orbital dermatitis or trauma, infections or chronic eye conditions that may affect the study outcome.
  • Has systemic illness which affects the eyes, including diabetes, thyroid disease, sarcoidosis, hypertension, atherosclerosis, lupus, multiple sclerosis, sickle cell disease, AIDs (Acquired Immune Deficiency Syndrome), severer rheumatoid arthritis. results as determined by the investigator.
  • Must not have a history of pre-existing sensitivity or other types of allergy to any eye products.
  • Must not have received and used an Investigational New Drug within the thirty days immediately preceding the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02714166


Locations
Layout table for location information
United States, Florida
St. Petersburg, Florida, United States, 33714
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02714166    
Other Study ID Numbers: 18766
First Posted: March 21, 2016    Key Record Dates
Last Update Posted: March 30, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Sunscreening Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Dermatologic Agents